Journals / MN Kardiyoloji / 2014 / Cilt: 21 - Sayı: 1

Inhaled nitric oxide therapy: cost analysis

İnhale nitrik oksit tedavisi: maliyet analizi

Pages
33–43
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: Because the devices measure the variety in treatment and the gas spent are not being used in Turkey, it was concluded that it would be very difficult to determine a standard amount of money for session per day or hour.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Social Security Institution General Health Insurance Medical Goods Department has requested a suggestion on the dosage of daily nitric oxide (NO) use and treatment expenses to be used in the Health Practice Documents, its attachments and lists.
📊
Key Findings & Data:Material and Method: When analyzed in the NO tubes, it was seen that the hospitals met the expenses of 93.58% of all the purchase in 2012, and 82.21% of the purchases in 2013 by 8 hospitals.
💡
Conclusion & Impact:Results: Because the devices measure the variety in treatment and the gas spent are not being used in Turkey, it was concluded that it would be very difficult to determine a standard amount of money for session per day or hour.
🔬Design:Research Article
📍Scope:2012 Verileri
⚙️Variables:Domain Parameters

Abstract

Aim: Social Security Institution General Health Insurance Medical Goods Department has requested a suggestion on the dosage of daily nitric oxide (NO) use and treatment expenses to be used in the Health Practice Documents, its attachments and lists. Material and Method: When analyzed in the NO tubes, it was seen that the hospitals met the expenses of 93.58% of all the purchase in 2012, and 82.21% of the purchases in 2013 by 8 hospitals. Because our Institution represents 80-90% of all the hospitals, the ex- pense study was conducted at these hospitals. Results: Because the devices measure the variety in treatment and the gas spent are not being used in Turkey, it was concluded that it would be very difficult to determine a standard amount of money for session per day or hour. For this reason, it was decided that it would be more accurate that the whole treatment and an average treatment price be determined. Conclusion: The average installation expense for NO is 4.539.17 TL per patient at each hospital. It is much higher than the expense of any operation.

Özet

Amaç: Sosyal Güvenlik Kurumu (SGK) Genel Sağlık Sigortası Tıbbi Malzeme Daire Başkanlığı’nca Sağlık Uygulama Tebliği (SUT) ve eki listelere yönelik mevzuat çalışmaları kapsamında, günlük kullanılabilecek nitrik oksit dozlarına ve tedavi maliyetlerine ilişkin görüş ta- lep edilmiştir. Gereç ve Yöntem: Nitrik oksit (NO) tüpleri bazında incelendiğinde; 2012 yılındaki tüm alımların %93,58’ini, 2013 yılındaki tüm alım- ların ise %82,21’ini 8 hastanenin yaptığı görülmüştür. Kurumumuz hastanelerinin %80-90’ını temsil ettiğinden dolayı maliyet çalışması bu hastanelerde gerçekleştirilmiştir. Bulgular: NO tedavisinde tedavinin değişkenliği ve harcanan gazın miktarını gösteren ölçüm cihazlarının ülkemizde henüz kullanılmı- yor olması nedeni ile standart bir seans/saat/gün başına ücret belirlenmesinin çok güç olduğu sonucuna varılmıştır. Bu nedenle tüm tedavinin bir paket işlem olarak ele alınıp, hasta başına ortalama bir işlem bedeli belirlemenin daha doğru olacağı kanaati hasıl ol- muştur. Sonuç: NO inhalasyonu için zorunlu olarak hastanelerimizce katlanılan hasta başı ortalama külfet 4.539.17 TL olup, birçok ameliyatın işlem bedelinden dahi yüksek olarak saptanmıştır.

🔖

Cite This Article

BENER, S., BALBAY, Y., GÜNGÖR, F., KODALAK, F., HEKİM, S., ÇAY, S. (2014). Inhaled nitric oxide therapy: cost analysis. MN Kardiyoloji, Cilt: 21 - Sayı: 1, 33–43. https://ajindex.com/articles/297257

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (7)

  1. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-de- rived relaxing factor. Nature 1987;327:524-26
  2. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and re- leased from artery and vein is nitric oxide. Proc Natl Acad Sci USA 1987;84:9265-9
  3. Moncada S, Higgs A. The L-Arginine - Nitric Oxide Pathway. N Engl J Med 1993;329:2002-11
  4. Nathan C. Nitric oxide as a secretory product of mam- malian cells. FASEB 1992;6:3051-64
  5. Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, Stone D, Wallwork J. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 1991;338:1173-4
  6. Corning HS. Nitric Oxide. RC Educatıonal Consultıng Servıces, INC. www.RCECS.com 7. Subhedar NV, Jauhari P, Natarajan R. Cost of inhaled ni- tric oxide therapy in neonates. Lancet. 2002;359:1781-2
  7. Sağlık Bakanlığı Malzeme Kaynakları Yönetim Sistemi (MKYS), 2013